|
Gene: RHOC |
Gene summary for RHOC |
Gene summary. |
Gene information | Species | Human | Gene symbol | RHOC | Gene ID | 389 |
Gene name | ras homolog family member C | |
Gene Alias | ARH9 | |
Cytomap | 1p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | A0A024R0I3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389 | RHOC | C30 | Human | Oral cavity | OSCC | 3.31e-53 | 3.72e+00 | 0.3055 |
389 | RHOC | C38 | Human | Oral cavity | OSCC | 1.24e-20 | 2.24e+00 | 0.172 |
389 | RHOC | C43 | Human | Oral cavity | OSCC | 3.49e-104 | 1.99e+00 | 0.1704 |
389 | RHOC | C46 | Human | Oral cavity | OSCC | 4.94e-73 | 1.89e+00 | 0.1673 |
389 | RHOC | C51 | Human | Oral cavity | OSCC | 1.34e-28 | 2.13e+00 | 0.2674 |
389 | RHOC | C57 | Human | Oral cavity | OSCC | 3.13e-57 | 2.15e+00 | 0.1679 |
389 | RHOC | C06 | Human | Oral cavity | OSCC | 8.98e-21 | 3.30e+00 | 0.2699 |
389 | RHOC | C07 | Human | Oral cavity | OSCC | 1.17e-10 | 2.00e+00 | 0.2491 |
389 | RHOC | C08 | Human | Oral cavity | OSCC | 6.92e-94 | 2.30e+00 | 0.1919 |
389 | RHOC | C09 | Human | Oral cavity | OSCC | 7.03e-41 | 1.53e+00 | 0.1431 |
389 | RHOC | LN22 | Human | Oral cavity | OSCC | 2.09e-12 | 1.65e+00 | 0.1733 |
389 | RHOC | LN38 | Human | Oral cavity | OSCC | 2.66e-05 | 1.43e+00 | 0.168 |
389 | RHOC | LN46 | Human | Oral cavity | OSCC | 8.50e-24 | 1.56e+00 | 0.1666 |
389 | RHOC | LP15 | Human | Oral cavity | LP | 8.84e-15 | 2.36e+00 | 0.2174 |
389 | RHOC | LP16 | Human | Oral cavity | LP | 7.67e-03 | 1.49e+00 | 0.1055 |
389 | RHOC | LP17 | Human | Oral cavity | LP | 1.05e-18 | 2.23e+00 | 0.2349 |
389 | RHOC | NEOLP-3 | Human | Oral cavity | NEOLP | 2.58e-03 | 1.61e-01 | -0.0191 |
389 | RHOC | SYSMH1 | Human | Oral cavity | OSCC | 3.88e-33 | 9.58e-01 | 0.1127 |
389 | RHOC | SYSMH2 | Human | Oral cavity | OSCC | 1.52e-17 | 9.46e-01 | 0.2326 |
389 | RHOC | SYSMH3 | Human | Oral cavity | OSCC | 6.06e-38 | 1.39e+00 | 0.2442 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00432549 | Breast | Precancer | regulation of protein-containing complex assembly | 50/1080 | 428/18723 | 1.63e-06 | 5.97e-05 | 50 |
GO:00313349 | Breast | Precancer | positive regulation of protein-containing complex assembly | 33/1080 | 237/18723 | 2.39e-06 | 8.21e-05 | 33 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:19029059 | Breast | Precancer | positive regulation of supramolecular fiber organization | 28/1080 | 209/18723 | 2.79e-05 | 6.28e-04 | 28 |
GO:19029039 | Breast | Precancer | regulation of supramolecular fiber organization | 42/1080 | 383/18723 | 4.92e-05 | 1.04e-03 | 42 |
GO:00329709 | Breast | Precancer | regulation of actin filament-based process | 42/1080 | 397/18723 | 1.11e-04 | 2.01e-03 | 42 |
GO:00514959 | Breast | Precancer | positive regulation of cytoskeleton organization | 28/1080 | 226/18723 | 1.13e-04 | 2.04e-03 | 28 |
GO:00070159 | Breast | Precancer | actin filament organization | 44/1080 | 442/18723 | 3.02e-04 | 4.35e-03 | 44 |
GO:00329569 | Breast | Precancer | regulation of actin cytoskeleton organization | 36/1080 | 358/18723 | 8.56e-04 | 9.88e-03 | 36 |
GO:01100539 | Breast | Precancer | regulation of actin filament organization | 29/1080 | 278/18723 | 1.50e-03 | 1.55e-02 | 29 |
GO:00514929 | Breast | Precancer | regulation of stress fiber assembly | 13/1080 | 91/18723 | 2.11e-03 | 2.00e-02 | 13 |
GO:00514965 | Breast | Precancer | positive regulation of stress fiber assembly | 9/1080 | 52/18723 | 2.67e-03 | 2.36e-02 | 9 |
GO:00322338 | Breast | Precancer | positive regulation of actin filament bundle assembly | 10/1080 | 63/18723 | 3.07e-03 | 2.62e-02 | 10 |
GO:00300389 | Breast | Precancer | contractile actin filament bundle assembly | 14/1080 | 106/18723 | 3.07e-03 | 2.62e-02 | 14 |
GO:00431499 | Breast | Precancer | stress fiber assembly | 14/1080 | 106/18723 | 3.07e-03 | 2.62e-02 | 14 |
GO:00071638 | Breast | Precancer | establishment or maintenance of cell polarity | 23/1080 | 218/18723 | 3.82e-03 | 3.06e-02 | 23 |
GO:00510179 | Breast | Precancer | actin filament bundle assembly | 18/1080 | 157/18723 | 4.17e-03 | 3.28e-02 | 18 |
GO:01100209 | Breast | Precancer | regulation of actomyosin structure organization | 13/1080 | 100/18723 | 4.87e-03 | 3.68e-02 | 13 |
GO:00615729 | Breast | Precancer | actin filament bundle organization | 18/1080 | 161/18723 | 5.43e-03 | 4.01e-02 | 18 |
GO:00072496 | Breast | Precancer | I-kappaB kinase/NF-kappaB signaling | 27/1080 | 281/18723 | 6.58e-03 | 4.53e-02 | 27 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RHOC | SNV | Missense_Mutation | novel | c.125N>G | p.Tyr42Cys | p.Y42C | P08134 | protein_coding | deleterious(0.02) | possibly_damaging(0.654) | TCGA-AC-A3OD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOC | SNV | Missense_Mutation | novel | c.424N>A | p.Glu142Lys | p.E142K | P08134 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
RHOC | insertion | Nonsense_Mutation | novel | c.12_13insTGGCCCTCTGAGGGCATACTACTGTTGAGGTTTTGA | p.Ile4_Arg5insTrpProSerGluGlyIleLeuLeuLeuArgPheTer | p.I4_R5insWPSEGILLLRF* | P08134 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
RHOC | SNV | Missense_Mutation | c.70G>A | p.Val24Ile | p.V24I | P08134 | protein_coding | deleterious(0.03) | benign(0.058) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
RHOC | SNV | Missense_Mutation | novel | c.82N>T | p.Asp28Tyr | p.D28Y | P08134 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-VS-A957-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RHOC | SNV | Missense_Mutation | c.358N>A | p.Asp120Asn | p.D120N | P08134 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
RHOC | SNV | Missense_Mutation | novel | c.82G>T | p.Asp28Tyr | p.D28Y | P08134 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RHOC | SNV | Missense_Mutation | rs766734264 | c.526N>T | p.Arg176Trp | p.R176W | P08134 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOC | SNV | Missense_Mutation | c.193N>T | p.Asp65Tyr | p.D65Y | P08134 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-QG-A5YV-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR | |
RHOC | SNV | Missense_Mutation | rs779520374 | c.502C>T | p.Arg168Trp | p.R168W | P08134 | protein_coding | deleterious(0.03) | probably_damaging(0.982) | TCGA-EF-5830-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |